Windlas Biotech Limited

We are amongst the top five players in the domestic pharmaceutical formulations contract development and manufacturing organization (“CDMO”) industry in India in terms of revenue (Source: CRISIL Report). With over two decades of experience in manufacturing both solid and liquid pharmaceutical dosage forms and significant experience in providing specialized capabilities, including, high potency, controlled substances and low-solubility, we provide a comprehensive range of CDMO services ranging from product discovery, product development, licensing and commercial manufacturing of generic products, including complex generics, in compliance with current Good Manufacturing Practices (“GMP”) with a focus on improved safety, efficacy and cost. In Fiscal 2020, our market share was approximately 1.5% in terms of revenue in the domestic formulations CDMO industry (Source: CRISIL Report). In addition to providing services and products in the CDMO market, we also sell our own branded products in the trade generics and OTC markets as well as export generic products to several countries.

IPO Timeline:

Date of filing17 May 2021
IPO OpenYet to be declared
IPO closeYet to be declared
Allotment DateYet to be declared
Initiation of RefundsYet to be declared
Credit of shares in DematYet to be declared
Listing on exchangeYet to be declared

Issue Details:

ExchangeBSE, NSE
Issue Type
Face Value
Price Band
Lot Size
Issue Size
Offer for Sale
Fresh Issue

Subscription Quota:

CategoryQuota
QIB
NII
RII
Total

Subscription Status:

CategorySubscription
QIB
NII
RII
Total

Profit & Loss Statement (₹ in Cr) :

31 Dec 2020
(nine month)
31 March 202031 March 201931 March 2018
Total Revenue323331311357
Total Expense288299284337
Profit after Tax9.81663.711.2

Other Financials (₹ in Cr) :

31 Dec 202031 March 202031 March 201931 March 2018
Total Equity193210194125
Total Liability11912596143
Debt to equity0.620.600.491.14

Leave a Reply

Your email address will not be published. Required fields are marked *